FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
2019
Carlos J Diaz Osterman | Duygu Ozmadenci | Elizabeth G Kleinschmidt | Kristin N Taylor | Allison M Barrie | Shulin Jiang | Lisa M Bean | Florian J Sulzmaier | Christine Jean | Isabelle Tancioni | Kristen Anderson | Sean Uryu | Edward A Cordasco | Jian Li | Xiao Lei Chen | Guo Fu | Marjaana Ojalill | Pekka Rappu | Jyrki Heino | Adam M Mark | Guorong Xu | Kathleen M Fisch | Vihren N Kolev | David T Weaver | Jonathan A Pachter | Balázs Győrffy | Michael T McHale | Denise C Connolly | Alfredo Molinolo | Dwayne G Stupack | David D Schlaepfer
Gene copy number alterations, tumor cell stemness, and the development of platinum chemotherapy resistance contribute to high-grade serous ovarian cancer (HGSOC) recurrence. Stem phenotypes involving Wnt-β-catenin, aldehyde dehydrogenase activities, intrinsic platinum resistance, and tumorsphere formation are here associated with spontaneous gains in Kras, Myc and FAK (KMF) genes in a new aggressive murine model of ovarian cancer. Adhesion-independent FAK signaling sustained KMF and human tumorsphere proliferation as well as resistance to cisplatin cytotoxicity. Platinum-resistant tumorspheres can acquire a dependence on FAK for growth. Accordingly, increased FAK tyrosine phosphorylation was observed within HGSOC patient tumors surviving neo-adjuvant chemotherapy. Combining a FAK inhibitor with platinum overcame chemoresistance and triggered cell apoptosis. FAK transcriptomic analyses across knockout and reconstituted cells identified 135 targets, elevated in HGSOC, that were regulated by FAK activity and β-catenin including Myc, pluripotency and DNA repair genes. These studies reveal an oncogenic FAK signaling role supporting chemoresistance.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals